e-Article
Safety and Usage of C1-Inhibitor in Hereditary Angioedema: Berinert Registry Data
Document Type
Article
Author
Riedl, Marc A.; Bygum, Anette; Lumry, William; Magerl, Markus; Bernstein, Jonathan A.; Busse, Paula; Craig, Timothy; Frank, Michael M.; Edelman, Jonathan; Williams-Herman, Debora; Feuersenger, Henrike; Rojavin, Mikhail; Offenberger, Jacob; Levy, Robyn; Hurewitz, David; Li, H. Henry; Shapiro, Ralph; Bernstein, Jonathan; Craig, Timothy; Davis, Aaron; Rosch, Jeffrey; Fox, James; Janss, Gerti; Baker, James; Packer, Flint; Vegh, Art; Frank, Michael; Sher, Ellen; Busse, Paula; Wedner, James H.; Riedl, Marc; Lumry, William; Amrol, David; Gower, Richard; Silber, Glenn; Portnoy, Jay; Paris, Kenneth; Darter, Amy; Mumneh, Nayla; Petrov, Andrej; Schneider, Lynda; Martinez-Saguer, Inmaculada; Staubach-Renz, Petra; Maurer, Marcus; Bas, Murat; Aygören-Pürsün, Emel; Bygum, Anette; Wuillemin, Walter
Source
The Journal of Allergy and Clinical Immunology: In Practice; September-October 2016, Vol. 4 Issue: 5 p963-971, 9p
Subject
Language
ISSN
22132198
Abstract
The plasma-derived, highly purified, nanofiltered C1-inhibitor concentrate (Berinert; “pnfC1-INH”) is approved in the United States for treating hereditary angioedema (HAE) attacks and in many European countries for attack treatment and short-term prophylaxis.